BDPT · XBRL financial data

BioAdaptives financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BDPT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	16	20	17	29	13	18
Cost of revenue	10	10	10	18	9	6
Gross profit	6	10	7	11	4	12
General and administrative	72	268	254	101	335	821
Total operating expenses	260	646	429	240	606	1,055
Operating income (loss)	—	—	(422)	(229)	(602)	(1,042)
Interest expense	230	272	289	163	92	71
Other income (expense)	—	(414)	(474)	(484)	(297)	(516)
Income tax expense (benefit)	0	0	0	—	0	0
Net income (loss)	(847)	(1,050)	(896)	(712)	(899)	(1,558)
Earnings per share, basic USD per share	—	—	—	(0.12)	(0.11)	—
Earnings per share, diluted USD per share	—	—	—	—	(0.11)	(0.15)
Weighted average shares, basic thousands of shares	—	—	—	5,972	8,215	—
Weighted average shares, diluted thousands of shares	—	—	—	—	8,215	10,073

† Share count changed about 1/107 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BDPT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	5	83	25	61	262	215
Marketable securities	0	0	0	0	0	0
Inventory	14	5	9	15	19	45
Total current assets	19	89	34	89	262	212
Property and equipment, net	—	—	—	—	0	14
Total assets	19	149	37	104	262	226
Accounts payable	—	2	7	—	—	—
Accrued liabilities	0	63	1	138	172	216
Total current liabilities	1,398	1,242	1,489	1,751	1,726	2,356
Total liabilities	1,398	1,242	1,489	1,751	1,726	2,356
Accumulated deficit	(5,606)	(6,656)	(7,552)	(8,264)	(9,163)	(10,721)
Total stockholders' equity	(1,379)	(1,093)	(1,452)	(1,647)	(1,464)	(2,130)
Total liabilities and equity	19	149	37	104	262	226
Common shares outstanding (cover page) thousands of shares	33,022	55,730	355,633	972,161	9,049	12,009

† Share count changed about 1/107 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BDPT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(847)	(1,050)	(896)	(712)	(899)	(1,558)
Stock-based compensation	47	164	0	—	—	29
Net cash from operating activities	(107)	(159)	(227)	(224)	(250)	(516)
Purchases of property and equipment	—	—	—	—	0	18
Net cash from investing activities	—	—	—	—	0	(18)
Proceeds from issuing common stock	—	565	272	178	0	—
Net cash from financing activities	99	237	170	259	326	555
Net change in cash	(8)	78	(58)	—	—	—

† Share count changed about 1/107 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Bioadaptives	29	5	(44)*	196.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
CNBX Pharmaceuticals	9.5	0	(48)*	1.6B	0.2 quarters	Q3 FY26 10-QMay 31, 2026
Kaya Holdings	26	5.4	(68)*	686.4M	0.4 quarters	Q3 FY25 10-QSep 30, 2025
Eloxx Pharmaceuticals	61,960	not reported	(4,789)*	4.0M	12.9 quarters	Q2 FY26 10-QJun 30, 2026
NovAccess Global	21	0*	(55)*	61.7M	0.4 quarters	Q4 FY24 10-KSep 30, 2024
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.